After FDA holdup, Novavax secures full approval for protein-based COVID vaccine
The FDA has approved Novavax’s COVID vaccine in adults ages 65 years and older and in people between the ages of 12 and 64 who have at least one underlying health condition that puts them at high risk for severe COVID outcomes. Though not in the broad population the company had hoped for, Novavax feels confident the approval offers a strong market opportunity.
The FDA has approved Novavax’s COVID vaccine in adults ages 65 years and older and in people between the ages of 12 and 64 who have at least one underlying health condition that puts them at high risk for severe COVID outcomes. Though not in the broad population the company had hoped for, Novavax feels confident the approval offers a strong market opportunity.
